TRIAL (Therapeutic Research Institute and Lab) vs a first-in-human device CRO

What TRIAL publishes in Guatemala, and how that differs from a device first-in-human plan and from a commercial MSPAS registration.

Regulatory sources checked November 7, 2026. General sponsor guidance, not legal advice or an approval guarantee.

If you searched for TRIAL (Therapeutic Research Institute and Lab), you are probably building a shortlist. This note uses only what TRIAL publishes about itself. It does not invent a relationship, a shared study, or a preference TRIAL has not stated. Public pages were reviewed for this comparison in October 2026. Their claims are theirs.

What TRIAL publishes

TRIAL describes itself as a CRO and site management organization in Guatemala. Its public services include regulatory support, investigational-product logistics such as storage and distribution, research-site support, and continuing education. The organization site is trialresearch.org. Confirm any engagement, location, and service directly with TRIAL.

How to read bioaccess® next to that description

bioaccess® is a first-in-human and early-feasibility CRO for medical devices, with a Miami base and Latin American work since 2010. That sentence is a company description. It is not a claim that a named Guatemala study is open, and it is not a claim that bioaccess® holds an independent registration subscription in Guatemala.

A Guatemala device investigation still has to follow the MSPAS / DRCPFA pathway on clinical trials in Guatemala: ethics approval before the Department, a device dossier under section 43 rather than a drug Phase I file, and a complete-file authority clock that is not a startup promise.

After a study, commercial registration is a separate MSPAS file under Acuerdo Gubernativo 712-99 and Norma Técnica 37. On the Guatemala registration page, bioaccess® describes manufacturer-funded processing, not a Guatemala holder subscription. A multi-country holder service, where it exists for other markets, does not authorize a Guatemala trial and does not make bioaccess® the Guatemalan titular.

Ask every organization on the shortlist, including TRIAL and bioaccess®, for the same things: the protocol, the ethics committee, the monitoring plan, and how any foreign data would be discussed with FDA. Eligibility under 21 CFR 812.28 is conditional. It is not clearance.

Other comparisons sit on the compare hub. This page does not rank CROs by a speed or cost percentage.

Request a first-in-human study proposal when you want bioaccess® to look at a specific device protocol.

Frequently asked questions

Is TRIAL a bioaccess® partner?

This page does not say that. It reports services TRIAL publishes and separates them from a device first-in-human plan.

Does a regional holder service include a Guatemala trial approval?

No. Investigational authorization and commercial registration are different files. Guatemala commercial processing is not a holder subscription.

← Back to Blog · Contact bioaccess®